Drug Type Bispecific antibody |
Synonyms SH 009, SH-009, SH009 + [2] |
Target |
Action inhibitors |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | China | 21 May 2025 | |
| Esophageal Carcinoma | Phase 1 | China | 16 May 2025 | |
| Hepatocellular Carcinoma | Phase 1 | China | 16 May 2025 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 16 May 2025 | |
| Metastatic breast cancer | Phase 1 | China | 16 May 2025 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 1 | China | 16 May 2025 | |
| Stomach Cancer | Phase 1 | China | 16 May 2025 | |
| Advanced cancer | Phase 1 | China | 22 Jul 2022 |






